Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARKLE trial of crizanlizumab versus placebo in adolescents and adults with sickle cell disease and frequent vaso-occlusive crises
PACTR202411757595104Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Crizanlizumab with Placebo comparator (2 arms). Primary endpoint: Annualized rate of vaso-occlusive crises. Started Oct 2024; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202411757595104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202411757595104.